HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

INNOGEN-B

4.080

-0.130-3.09%

Volume:9.61M

Turnover:39.19M

Market Cap:1.86B

PE:-4.43

High:4.230

Open:4.215

Low:4.010

Close:4.210

52wk High:53.000

52wk Low:4.010

Shares:457.00M

HK Float Shares:420.29M

Volume Ratio:0.70

T/O Rate:2.29%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.922

ROE:-36.91%

ROA:-17.30%

PB:1.52

PE(LYR):-4.43

PS:12.15

Loading ...

Overview Company News Filings

BUZZ-Guangzhou Innogen climbs on clinical trials approval on obesity drug

BRIEF-Guangzhou Innogen Pharmaceutical Says On 17 June, Receives Approval To Start Phase IB Trial

Innogen Pharma Gets Clinical Trial Nod for Obesity Drug in China

MT Newswires Live

INNOGEN-B Receives NMPA Clearance for Phase Ib Trial of Esupaglutide Alpha in Adolescent Obesity

Guangzhou Innogen Pharmaceutical Group Co - on 17 June, Receives China Approval to Start Phase Ib Trial for Efsubaglutide Alfa in Adolescent Obesity

THOMSON REUTERS

Innogen Pharmaceutical Sets 29 June 2026 AGM; Seeks to Scrap Supervisory Committee and Launch Share Award Scheme

Bulletin Express

INNOGEN-B AGM Agenda: Share Award Scheme, 20% Issue Mandate, Supervisory Committee Abolition

Bulletin Express

INNOGEN-B Shares Surge Over 9% as Its Proprietary Drug Features at Major Diabetes Conference

INNOGEN-B’s May 2026 Monthly Return Shows Stable Share Structure and Compliance With Public Float Rules

Bulletin Express

INNOGEN-B Shares Surge Over 6% Ahead of Key Clinical Data Presentation at ADA 2026

Movement Alert｜Yinnuo Pharma-B Rises 10.68% in Regular Trading, Share Award Plan and Commercialization Acceleration Drive Gains

INNOGEN-B Proposes Adoption of Share Incentive Scheme

Guangzhou Innogen proposes 10-year share award scheme with 10% issuance cap

Guangzhou Innogen Pharmaceutical proposes re-election of entire board slate for three-year term

Innogen says Phase IIb trial shows efsubaglutide alfa cuts weight up to 10.58% in adults with obesity

Stock Track | INNOGEN-B Plummets 6.52% Intraday as Cornerstone Investor Lock-ups Expire

Hong Kong Stocks Midday Recap: Hang Seng Index Dips 0.87%, Robotics Sector Surges Against Market Trend

Stock Track | INNOGEN-B Plummets 5.46% Intraday as Lock-Up Period Expires and Financial Losses Widen

INNOGEN-B Shares Extend Losses as Lock-Up Period Nears End

INNOGEN-B Shares Plunge Over 9% Following Previous Day's Surge, Lock-Up Period for Cornerstone Investors Nears End

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/02591/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02591","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"INNOGEN-B","latestPrice":4.08,"timestamp":1787299688008,"preClose":4.21,"halted":0,"volume":9608610,"delay":0,"changeRate":-0.03087885985748216,"floatShares":420285370,"shares":457000000,"eps":-0.9218411498561111,"marketStatus":"Not Yet Opened","change":-0.13,"latestTime":"08-21 16:08:08","open":4.215,"high":4.23,"low":4.01,"amount":39193170,"amplitude":0.052257,"askPrice":4.08,"askSize":55400,"bidPrice":4.07,"bidSize":8200,"shortable":3,"etf":0,"ttmEps":-0.9650159885202579,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":4.21,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.7016963557043266,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","floatShares":420285370,"roa":"-17.30%","roe":"-36.91%","lyrEps":-0.921841,"volumeRatio":0.7016963557043266,"shares":457000000,"dividePrice":0,"high":4.23,"amplitude":0.052257,"preClose":4.21,"low":4.01,"week52Low":4.01,"pbRate":"1.52","psRate":"12.15","week52High":53,"institutionHeld":0,"latestPrice":4.08,"committee":-0.742138,"eps":-0.9218411498561111,"divideRate":0,"volume":9608610,"delay":0,"ttmEps":-0.9650159885202579,"open":4.215,"prevYearClose":30.64,"prevWeekClose":6.61,"prevMonthClose":7.26,"prevQuarterClose":7.09,"fiveDayClose":6.61,"twentyDayClose":7.59,"sixtyDayClose":11.84,"earningDate":1787587200000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02591\",params:#limit:5,,,undefined,":[{"date":"2026-08-25","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787621400000,"name":null,"time":"","dateTimestamp":1787587200000,"actualEps":null},{"market":"HK","date":"2026-03-23","symbol":"02591","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774195200000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-29","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02591\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02591\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1775750400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02591\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02591","date":"2026-08-21","current":-4.227909,"percent":1,"low":-137.156472,"twenty":-69.656366,"median":-50.052949,"eighty":-12.083492,"high":-5.675745,"avg":-45.707081,"sd":29.956855,"marketCap":1863822943},"quantilePoints":[{"date":"2025-08-15","current":-137.156472,"twenty":-137.156472,"median":-137.156472,"eighty":-137.156472,"marketCap":26152907730},{"date":"2025-08-22","current":-127.373977,"twenty":-129.344203,"median":-127.373977,"eighty":-126.417438,"marketCap":24211425497},{"date":"2025-08-29","current":-106.390102,"twenty":-127.373977,"median":-126.095992,"eighty":-114.007182,"marketCap":20319324643},{"date":"2025-09-05","current":-78.151342,"twenty":-127.373977,"median":-117.586994,"eighty":-99.491273,"marketCap":18939730209},{"date":"2025-09-12","current":-83.843855,"twenty":-126.417438,"median":-105.433356,"eighty":-83.374192,"marketCap":20355870191},{"date":"2025-09-19","current":-79.271387,"twenty":-126.095992,"median":-93.890147,"eighty":-81.90749,"marketCap":19232094592},{"date":"2025-09-26","current":-78.986763,"twenty":-125.916102,"median":-85.498552,"eighty":-79.429082,"marketCap":19113321562},{"date":"2025-10-03","current":-76.5387,"twenty":-122.116665,"median":-83.843855,"eighty":-78.76383,"marketCap":18565138343},{"date":"2025-10-10","current":-69.068341,"twenty":-116.871032,"median":-83.374192,"eighty":-77.810518,"marketCap":16728724560},{"date":"2025-10-17","current":-67.838616,"twenty":-109.436934,"median":-79.738352,"eighty":-74.826182,"marketCap":16418087403},{"date":"2025-10-24","current":-59.813644,"twenty":-105.816054,"median":-79.429082,"eighty":-68.576451,"marketCap":14481173363},{"date":"2025-10-31","current":-57.61442,"twenty":-103.460611,"median":-78.986763,"eighty":-66.346017,"marketCap":13969535692},{"date":"2025-11-07","current":-56.556997,"twenty":-100.097405,"median":-78.243448,"eighty":-63.14919,"marketCap":13704580470},{"date":"2025-11-14","current":-61.96171,"twenty":-95.010372,"median":-77.299283,"eighty":-61.326336,"marketCap":15056765743},{"date":"2025-11-21","current":-54.467459,"twenty":-87.179427,"median":-75.823033,"eighty":-60.1184,"marketCap":13229488347},{"date":"2025-11-28","current":-82.342484,"twenty":-85.508442,"median":-76.5387,"eighty":-60.703449,"marketCap":20072642195},{"date":"2025-12-05","current":-82.313405,"twenty":-85.248884,"median":-75.823033,"eighty":-61.326336,"marketCap":20100051356},{"date":"2025-12-12","current":-63.824496,"twenty":-84.462171,"median":-74.404407,"eighty":-61.326336,"marketCap":15614085348},{"date":"2025-12-19","current":-62.072323,"twenty":-83.725798,"median":-74.049705,"eighty":-60.286674,"marketCap":15221220708},{"date":"2025-12-24","current":-59.762449,"twenty":-83.548712,"median":-73.276127,"eighty":-59.816947,"marketCap":14700446650},{"date":"2026-01-02","current":-56.27243,"twenty":-83.409096,"median":-71.366231,"eighty":-59.572219,"marketCap":13896444596},{"date":"2026-01-09","current":-57.1291,"twenty":-82.548826,"median":-69.803372,"eighty":-58.239982,"marketCap":14143127045},{"date":"2026-01-16","current":-56.980838,"twenty":-82.319221,"median":-67.499105,"eighty":-57.682607,"marketCap":14152263432},{"date":"2026-01-23","current":-58.213825,"twenty":-82.096799,"median":-66.291021,"eighty":-57.601428,"marketCap":14444627815},{"date":"2026-01-30","current":-54.613459,"twenty":-81.934522,"median":-64.906051,"eighty":-57.510573,"marketCap":13613216600},{"date":"2026-02-06","current":-49.064319,"twenty":-80.235292,"median":-63.834,"eighty":-57.242442,"marketCap":12261031327},{"date":"2026-02-13","current":-50.165477,"twenty":-79.691019,"median":-62.941647,"eighty":-57.039695,"marketCap":12608214032},{"date":"2026-02-20","current":-50.419859,"twenty":-79.623791,"median":-62.643943,"eighty":-56.891323,"marketCap":12653895967},{"date":"2026-02-27","current":-50.052949,"twenty":-79.470699,"median":-62.017016,"eighty":-56.651056,"marketCap":12699577902},{"date":"2026-03-06","current":-43.88908,"twenty":-79.397543,"median":-60.902753,"eighty":-56.29247,"marketCap":11045891858},{"date":"2026-03-13","current":-39.965904,"twenty":-79.214462,"median":-60.292057,"eighty":-54.71959,"marketCap":10104843999},{"date":"2026-03-20","current":-39.174717,"twenty":-78.964109,"median":-59.813644,"eighty":-50.865048,"marketCap":9867297938},{"date":"2026-03-27","current":-24.701097,"twenty":-78.775514,"median":-59.491697,"eighty":-50.290678,"marketCap":9547524394},{"date":"2026-04-02","current":-24.535908,"twenty":-78.383597,"median":-58.823921,"eighty":-50.052949,"marketCap":9529251620},{"date":"2026-04-10","current":-24.978414,"twenty":-78.348547,"median":-58.584467,"eighty":-49.631191,"marketCap":9775934068},{"date":"2026-04-17","current":-23.474521,"twenty":-78.227102,"median":-58.112982,"eighty":-48.421657,"marketCap":9191205301},{"date":"2026-04-24","current":-19.658213,"twenty":-78.155492,"median":-57.844151,"eighty":-44.116877,"marketCap":7697406030},{"date":"2026-04-30","current":-16.329046,"twenty":-77.825679,"median":-57.660489,"eighty":-41.074266,"marketCap":6395470886},{"date":"2026-05-08","current":-17.822364,"twenty":-77.322024,"median":-57.626503,"eighty":-40.478309,"marketCap":5778764764},{"date":"2026-05-15","current":-17.368107,"twenty":-77.157551,"median":-57.517602,"eighty":-40.012158,"marketCap":5646287153},{"date":"2026-05-22","current":-17.112125,"twenty":-76.782452,"median":-57.446424,"eighty":-25.37304,"marketCap":5550355090},{"date":"2026-05-29","current":-15.607197,"twenty":-76.252433,"median":-57.23775,"eighty":-24.916387,"marketCap":5079831160},{"date":"2026-06-05","current":-14.014909,"twenty":-75.020932,"median":-57.073515,"eighty":-24.414835,"marketCap":4568193490},{"date":"2026-06-12","current":-11.752443,"twenty":-74.621039,"median":-56.924891,"eighty":-23.900197,"marketCap":3828146144},{"date":"2026-06-18","current":-10.549084,"twenty":-74.404407,"median":-56.73827,"eighty":-23.474521,"marketCap":3444417891},{"date":"2026-06-26","current":-9.60263,"twenty":-74.160764,"median":-56.642046,"eighty":-20.865982,"marketCap":3120076153},{"date":"2026-07-03","current":-11.351574,"twenty":-74.088566,"median":-56.533624,"eighty":-19.581214,"marketCap":3691100339},{"date":"2026-07-10","current":-11.238926,"twenty":-74.037218,"median":-56.208644,"eighty":-19.055481,"marketCap":3649986598},{"date":"2026-07-17","current":-10.540302,"twenty":-73.42668,"median":-55.144116,"eighty":-17.753872,"marketCap":3435281504},{"date":"2026-07-24","current":-10.636027,"twenty":-71.947117,"median":-53.621015,"eighty":-17.028947,"marketCap":3467258858},{"date":"2026-07-31","current":-10.1543,"twenty":-71.465685,"median":-51.153424,"eighty":-16.590446,"marketCap":3316508473},{"date":"2026-08-07","current":-10.609247,"twenty":-70.999854,"median":-50.412223,"eighty":-15.817726,"marketCap":3471827052},{"date":"2026-08-14","current":-9.215586,"twenty":-70.625283,"median":-50.222782,"eighty":-14.020929,"marketCap":3019575896},{"date":"2026-08-21","current":-5.675745,"twenty":-69.656366,"median":-50.052949,"eighty":-12.083492,"marketCap":1863822943}],"updateTime":1787508833990},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02591\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645044484","title":"BUZZ-Guangzhou Innogen climbs on clinical trials approval on obesity drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2645044484","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645044484?lang=en_us&edition=fundamental","pubTime":"2026-06-22 15:36","pubTimestamp":1782113804,"startTime":"0","endTime":"0","summary":"BUZZ-Guangzhou Innogen climbs on clinical trials approval on obesity drug** Shares of Guangzhou Innogen Pharmaceutical Group 2591.HK climb 4.4% to HK$7.87, on course for the biggest one-day pct gain since May 19** Hong Kong-listed pharmaceutical products developer says it has received approval from China's National Medical Products Administration to commence Phase Ib clinical trials for its Efsubaglutide Alfa for the treatment of obesity in adolescents** Company expects to commence clinical trial in July 2026 and plans to enroll about 36 participants for the clinical trial** YTD, stock down 74.6%, Hang Seng Biotech Index .HSBIO donw 15.7%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL1N42U07V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645497610","title":"BRIEF-Guangzhou Innogen Pharmaceutical Says On 17 June, Receives Approval To Start Phase IB Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645497610","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645497610?lang=en_us&edition=fundamental","pubTime":"2026-06-22 14:48","pubTimestamp":1782110893,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Innogen Pharmaceutical Says On 17 June, Receives Approval To Start Phase IB Trial June 22  - Guangzhou Innogen Pharmaceutical Group Co Ltd 2591.HK:GUANGZHOU INNOGEN PHARMACEUTICAL GROUP CO - ON 17 JUNE, RECEIVES CHINA APPROVAL TO START PHASE IB TRIAL FOR EFSUBAGLUTIDE ALFA IN ADOLESCENT OBESITYFurther company coverage: 2591.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42S06K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645049125","title":"Innogen Pharma Gets Clinical Trial Nod for Obesity Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2645049125","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645049125?lang=en_us&edition=fundamental","pubTime":"2026-06-22 14:38","pubTimestamp":1782110339,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical  obtained approval to conduct phase Ib clinical trials for Efsubaglutide Alfa from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The drug is being tested for the treatment of obesity in adolescents.The company expects to begin the trial in July and enroll around 36 participants.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183559762","title":"INNOGEN-B Receives NMPA Clearance for Phase Ib Trial of Esupaglutide Alpha in Adolescent Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=1183559762","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183559762?lang=en_us&edition=fundamental","pubTime":"2026-06-22 12:49","pubTimestamp":1782103749,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) has announced that it received approval from China's National Medical Products Administration (NMPA) on June 17, 2026, to initiate a Phase Ib clinical trial for its drug candidate,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645704354","title":"Guangzhou Innogen Pharmaceutical Group Co - on 17 June, Receives China Approval to Start Phase Ib Trial for Efsubaglutide Alfa in Adolescent Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2645704354","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645704354?lang=en_us&edition=fundamental","pubTime":"2026-06-22 12:07","pubTimestamp":1782101278,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42S06K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185876958","title":"Innogen Pharmaceutical Sets 29 June 2026 AGM; Seeks to Scrap Supervisory Committee and Launch Share Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1185876958","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185876958?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:05","pubTimestamp":1780661110,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (“Innogen Pharmaceutical”), stock name INNOGEN-B, has issued a proxy circular outlining 24 resolutions to be tabled at its annual general meeting...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155251925","title":"INNOGEN-B AGM Agenda: Share Award Scheme, 20% Issue Mandate, Supervisory Committee Abolition","url":"https://stock-news.laohu8.com/highlight/detail?id=1155251925","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155251925?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:26","pubTimestamp":1780658769,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (“INNOGEN-B”) has published a circular for its Annual General Meeting (AGM) scheduled on 29 June 2026 in Shanghai, detailing 17 resolutions for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179509312","title":"INNOGEN-B Shares Surge Over 9% as Its Proprietary Drug Features at Major Diabetes Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1179509312","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179509312?lang=en_us&edition=fundamental","pubTime":"2026-06-05 11:12","pubTimestamp":1780629145,"startTime":"0","endTime":"0","summary":"Shares of INNOGEN-B (02591) surged more than 9% during the trading session. At the time of writing, the stock was up 3.21% to HK$10.28, with a turnover of HK$34.87 million. The catalyst for the move...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161","BK4585","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134785093","title":"INNOGEN-B’s May 2026 Monthly Return Shows Stable Share Structure and Compliance With Public Float Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=1134785093","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134785093?lang=en_us&edition=fundamental","pubTime":"2026-06-03 17:25","pubTimestamp":1780478754,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B) filed its Monthly Return for the period ended 31 May 2026, confirming that no changes occurred in either authorised or issued share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162227797","title":"INNOGEN-B Shares Surge Over 6% Ahead of Key Clinical Data Presentation at ADA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1162227797","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162227797?lang=en_us&edition=fundamental","pubTime":"2026-06-03 11:08","pubTimestamp":1780456101,"startTime":"0","endTime":"0","summary":"Shares of INNOGEN-B (02591) have risen more than 6%. At the time of writing, the stock is up 5.79% to HK$10.62, with a turnover of HK$90.33 million.The company has announced that it will present data...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VXUS","BK4588","02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116975222","title":"Movement Alert｜Yinnuo Pharma-B Rises 10.68% in Regular Trading, Share Award Plan and Commercialization Acceleration Drive Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1116975222","media":"Market Focus","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116975222?lang=en_us&edition=fundamental","pubTime":"2026-06-03 10:38","pubTimestamp":1780454339,"startTime":"0","endTime":"0","summary":"On June 3, Yinnuo Pharma-B rose 10.68% in regular trading, trading at 11.37 HKD/share, with trading volume of approximately 29.62 million HKD, significantly outperforming the broader Biotechnology...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132169066","title":"INNOGEN-B Proposes Adoption of Share Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1132169066","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132169066?lang=en_us&edition=fundamental","pubTime":"2026-06-01 22:40","pubTimestamp":1780324820,"startTime":"0","endTime":"0","summary":"INNOGEN-B (HKEX: 02591) has announced that its board of directors has proposed the adoption of a share reward plan.In accordance with the provisions of the company's articles of association, a...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK0251","BK1161","301122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640505849","title":"Guangzhou Innogen proposes 10-year share award scheme with 10% issuance cap","url":"https://stock-news.laohu8.com/highlight/detail?id=2640505849","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640505849?lang=en_us&edition=fundamental","pubTime":"2026-06-01 22:24","pubTimestamp":1780323892,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group proposed a 10-year Share Award Scheme, set to take effect on June 29, 2026, subject to shareholder approval.Scheme mandate caps awards at 10% of issued shares, excluding treasury shares; service provider awards capped at 1% as a sublimit.Based on 456,819,349 shares outstanding, the mandate limit equals 45,681,934 shares; the service provider sublimit equals 4,568,193 shares.Award shares may be satisfied via new H shares issued to a trustee, H shares bought in the market, or transfers of treasury shares.Vesting set by the board per grant; standard minimum vesting is 12 months, with limited exceptions for employee participants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLDJ9T3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640528579","title":"Guangzhou Innogen Pharmaceutical proposes re-election of entire board slate for three-year term","url":"https://stock-news.laohu8.com/highlight/detail?id=2640528579","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640528579?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:16","pubTimestamp":1780319760,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group set a shareholder vote to re-elect its entire board for a new three-year term.Proposed executive directors include founder-chairman and general manager Wang Qinghua, a metabolic-disease researcher with academic posts at the University of Toronto.Finance chief and board secretary Jiang Fan, a former strategy consultant and pharma investment-and-financing executive, is also up for re-election as an executive director.The board also proposed abolishing the supervisory committee, shifting oversight to a revised governance structure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLWqCX4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639620422","title":"Innogen says Phase IIb trial shows efsubaglutide alfa cuts weight up to 10.58% in adults with obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2639620422","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639620422?lang=en_us&edition=fundamental","pubTime":"2026-05-29 21:09","pubTimestamp":1780060155,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group flagged Phase IIb ENLIGHT results for obesity drug efsubaglutide alfa for presentation at the ADA meeting on June 8, 2026.The trial met its primary endpoint, with treated participants showing meaningful weight loss versus placebo and continued reduction through the dosing period.Innogen also reported improvements in body composition and metabolic markers, with weight loss driven mainly by fat rather than muscle.Safety looked manageable, with no hypoglycemia reported and mostly mild-to-moderate gastrointestinal side effects.The data set underpins plans to advance efsubaglutide alfa into Phase III development in obesity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL5SQw8z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160792896","title":"Stock Track | INNOGEN-B Plummets 6.52% Intraday as Cornerstone Investor Lock-ups Expire","url":"https://stock-news.laohu8.com/highlight/detail?id=1160792896","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160792896?lang=en_us&edition=fundamental","pubTime":"2026-05-15 12:12","pubTimestamp":1778818329,"startTime":"0","endTime":"0","summary":"INNOGEN-B's stock price plummeted 6.52% during Friday's intraday trading session, with the decline occurring around mid-morning.The sharp drop came as cornerstone investor lock-ups expired, allowing...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168389053","title":"Hong Kong Stocks Midday Recap: Hang Seng Index Dips 0.87%, Robotics Sector Surges Against Market Trend","url":"https://stock-news.laohu8.com/highlight/detail?id=1168389053","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168389053?lang=en_us&edition=fundamental","pubTime":"2026-05-15 12:09","pubTimestamp":1778818154,"startTime":"0","endTime":"0","summary":"The Hang Seng Index fell 0.87%, dropping 229 points to 26,159 in morning trading, while the Hang Seng Tech Index declined 1.26%. Morning session turnover reached HKD 151.1 billion. Tesla's...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00241","01801","06127","BK1116","002747","603986","00358","MCHmain","02692","HSI","BK1183","600362","01208","600699","02833","02715","513600","603127","HTImain","01888","03986","03317","02432","00699","BK4588","BK4585","HHImain","HSTECH","02591","003021","HSImain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147698784","title":"Stock Track | INNOGEN-B Plummets 5.46% Intraday as Lock-Up Period Expires and Financial Losses Widen","url":"https://stock-news.laohu8.com/highlight/detail?id=1147698784","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147698784?lang=en_us&edition=fundamental","pubTime":"2026-05-14 14:19","pubTimestamp":1778739592,"startTime":"0","endTime":"0","summary":"INNOGEN-B's stock price plummeted 5.46% during intraday trading on Thursday, continuing a downward trend following a significant surge earlier in the week.The decline comes ahead of the expiration of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122129496","title":"INNOGEN-B Shares Extend Losses as Lock-Up Period Nears End","url":"https://stock-news.laohu8.com/highlight/detail?id=1122129496","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122129496?lang=en_us&edition=fundamental","pubTime":"2026-05-14 14:18","pubTimestamp":1778739501,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) saw its share price decline by over 5%, continuing a downward trend after a significant surge earlier in the week. The stock had jumped more than 32% on heavy volume this past...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VXUS","BK1161","02591","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198355694","title":"INNOGEN-B Shares Plunge Over 9% Following Previous Day's Surge, Lock-Up Period for Cornerstone Investors Nears End","url":"https://stock-news.laohu8.com/highlight/detail?id=1198355694","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198355694?lang=en_us&edition=fundamental","pubTime":"2026-05-12 16:01","pubTimestamp":1778572884,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) fell more than 9% today, after closing up over 32% in the previous trading session. As of the time of writing, the stock was down 9.1% to HK$15.18, with a turnover of HK$131...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","02591","BK1161","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":92,"code":"91000000","status":"200"}]}}